Long-term use of brodalumab (SILIQ) improved skin clearance and quality of life in patients with moderate-to-severe psoriasis, according to a new study in the American Journal of Clinical Dermatology.
Overall, 181 patients received brodalumab for a median of 264 weeks. Brodalumab treatment resulted in rapid improvements in Psoriasis Area and Severity Index (PASI), Static Physician's Global Assessment (sPGA) and dermatology life quality index (DLQI) that were maintained through week 264. Overall, the study found that at brodalumab demonstrated skin clearance and improved quality of life, with an acceptable safety profile, throughout five years of treatment.
“These data add evidence that supports brodalumab as an efficacious and well-tolerated biologic therapy for the long-term treatment of moderate-to-severe plaque psoriasis, a lifelong disease,” the researchers conclude.